BCL2L10: A Drug Target / Disease Biomarker (G10017)

Target Name: BCL2L10

NCBI ID: G10017

BCL2L10

BCL2L10: A Drug Target / Disease Biomarker

BCL2L10 is a protein that is expressed in almost all human tissues and is involved in a variety of cellular processes. It is a key regulator of the B-cell response to cancer and has been implicated in the development and progression of many types of cancer.

Recent studies have identified BCL2L10 as a potential drug target for cancer treatment. BCL2L10 has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. It has also been shown to play a role in the development of cancer stem cells, which are cells that have the ability to give rise to all types of cancer.

In addition to its role in cancer, BCL2L10 is also involved in many other cellular processes that are important for cell survival. It plays a role in the regulation of cell division, cell signaling, and the immune response. It also has been shown to be involved in the formation of blood vessels, which is important for the delivery of oxygen and nutrients to cells.

Despite its involvement in so many cellular processes, BCL2L10 is relatively unstudied. There are currently no drugs that are specifically designed to target BCL2L10. However, researchers are actively working to identify potential drugs that can inhibit its activity.

One approach that researchers have taken to identify potential drugs that can inhibit BCL2L10 is to use a technique called high-throughput screening. This involves using a large number of small molecules to test their ability to interact with the protein.

In recent years, researchers have used high-throughput screening to identify a number of compounds that have the potential to inhibit BCL2L10. These compounds range from small molecules that are commonly found in the home to large molecules that are developed by pharmaceutical companies.

While many of these compounds show promise in inhibiting BCL2L10, it is important to note that not all of them are effective. Researchers have also found that some compounds can interact with BCL2L10 in unexpected ways, which can limit their effectiveness.

Despite the challenges, researchers are continuing to work on identifying new compounds that can inhibit BCL2L10. They hope that these compounds will eventually be used to develop new treatments for cancer.

In conclusion, BCL2L10 is a protein that is involved in a variety of cellular processes and has been implicated in the development and progression of many types of cancer. Its potential as a drug target makes it an attractive target for cancer researchers, and many compounds that have the potential to inhibit its activity are currently being tested. While there is still much work to be done, researchers are confident that they will eventually find effective treatments for cancer using these compounds.

Protein Name: BCL2 Like 10

Functions: Promotes cell survival by suppressing apoptosis induced by BAX but not BAK (PubMed:11689480, PubMed:11278245). Increases binding of AHCYL1/IRBIT to ITPR1 (PubMed:27995898). Reduces ITPR1-mediated calcium release from the endoplasmic reticulum cooperatively with AHCYL1/IRBIT under normal cellular conditions (PubMed:27995898). Under apoptotic stress conditions, dissociates from ITPR1 and is displaced from mitochondria-associated endoplasmic reticulum membranes, leading to increased Ca(2+) transfer to mitochondria which promotes apoptosis (PubMed:27995898). Required for the correct formation of the microtubule organizing center during oocyte cell division, potentially via regulation of protein abundance and localization of other microtubule organizing center components such as AURKA and TPX2 (By similarity)

The "BCL2L10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL2L10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets